Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.

Tarih
2011
Yazar
Castellano, D. E.
Bodrogi, I.
Booth, J. L.
Rosamilia, M.
Yuan, R. R.
Hawkins, R.
Knox, J. J.
Blank, C. U.
Gruenwald, V.
Karakiewicz, P. I.
Bavbek, S. E.
Miller, K.
Machiels, J. H.
Lee, S.
Larkin, J. M. G.
Bono, P.
Rha, S. Y.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/105800
Koleksiyonlar